QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: Ranibizumab Port-Delivery Implant Safety and Pharmacovigilance

Test your understanding of the concepts covered by Ranibizumab Port-Delivery Implant: Device, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 How should a report of implant dislocation with no immediate clinical consequence generally be handled?

Ignore it because there is no adverse reaction Record it only as a medication error Capture it as a device event and assess it for potential quality or use-related signal value Wait until vision loss occurs before entering it into surveillance

Question 2 of 10 Why is the implant lifecycle more informative than the interval since the last ranibizumab dose when reconstructing an event?

The implant eliminates the need to consider drug exposure timing Events may relate to implantation, device residence, refill, or later manipulation rather than only drug administration The date of the last dose is never relevant to an implant case Implant-related events occur only immediately after surgery

Question 3 of 10 A suspected retinal detachment occurs after a refill procedure. Which case detail is most important for causal reconstruction?

The retinal break or detachment pattern, timing, examination or imaging findings, repair and visual outcome Only the patient's refill appointment preference Only the total number of prior anti-VEGF injections Whether the patient had a systemic infection unrelated to the eye

Question 4 of 10 A patient has conjunctival erosion followed several weeks later by endophthalmitis. What is the most appropriate case-management implication?

Treat the two events as unrelated because they occurred on different dates Link the findings and assess whether implant exposure or compromised coverage increased infection risk Record only the later infection because it is more serious Record only the conjunctival finding because it preceded the infection

Question 5 of 10 Which interpretation of postoperative visual decline is most appropriate?

Any decline is an expected effect and requires no further evaluation Persistent or severe decline should prompt assessment for haemorrhage, detachment, infection, inflammation and device problems Visual decline after surgery is evidence of systemic anti-VEGF toxicity The event should be assigned to disease progression without reviewing procedure timing

Question 6 of 10 Why can refill interval differences between indications matter for pharmacovigilance?

They determine whether ranibizumab has any pharmacological activity They change the patient's cumulative exposure to refill-exchange procedures and associated risks They eliminate the need to record the indication They prove that events in different indications have different biological mechanisms

Question 7 of 10 What is the primary concern when a septum is dislodged during refill?

It is relevant only if the patient reports immediate pain It may affect device integrity, drug delivery or require corrective intervention It confirms that ranibizumab has caused retinal detachment It should be coded only as a manufacturing complaint with no clinical follow-up

Question 8 of 10 Why must intraocular inflammation after implantation be assessed for infection even when it appears compatible with sterile postoperative inflammation?

Sterile inflammation and infectious endophthalmitis can have overlapping clinical presentations All postoperative inflammation is necessarily infectious Inflammation cannot occur after implant surgery unless the device is defective Microbiological investigations are unnecessary when corticosteroids are used

Question 9 of 10 Which information would best help distinguish vitreous haemorrhage related to a procedure from haemorrhage associated with underlying retinal disease?

Procedure timing, antithrombotic therapy, retinal disease activity and need for vitrectomy Only the patient's history of seasonal allergies Only the number of ranibizumab refills planned for the future The presence or absence of systemic hypertension without ocular findings

Question 10 of 10 What is the principal pharmacovigilance significance of the boxed warning concerning endophthalmitis?

It indicates that endophthalmitis is exclusively caused by ranibizumab pharmacology It identifies a serious vision-threatening risk associated with the implant and a higher rate than monthly intravitreal ranibizumab injections It means suspected endophthalmitis does not require device or procedure information It applies only to patients receiving supplemental intravitreal injections

Knowledge Assessment: Ranibizumab Port-Delivery Implant Safety and Pharmacovigilance

Cookie Settings